Tracer library / [177Lu]Lu-DOTA-4AH29
[177Lu]Lu-DOTA-4AH29
Also written as [Lu-177]Lu-DOTA-4AH29
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Preclinical
- Syntheses indexed
- 2
What it is
- Compound class
- FAP-targeting single-domain antibody (sdAb)
- Target / mechanism
- Fibroblast activation protein alpha (FAP) targeting via single-domain antibody 4AH29 PMID 39266288
- Clinical application
- FAP-expressing tumors (pan-tumor stroma target); studied in pancreatic ductal adenocarcinoma PDX and glioma/colorectal xenograft models PMID 42364406
- Theranostic pair
- —
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | SPE | — | — | DOTA-4AH29 | 41688618 2026 EJNMMI Res sdAb 4AH29 was radiolabeled with 111In, 177Lu, and 225Ac at a selected pH for 30 min at 50 °C, then purified using NAP5 SEC |
| Manual synthesis | — | — | — | — | DOTA-4AH29 | 39266288 2024 J Nucl Med Information on chemical structures ... bioconjugation, radiochemistry, in vitro and in vivo assays, and dosimetry are available in the supplemental materials |
Need this precursor?We can point you to suppliers for [177Lu]Lu-DOTA-4AH29, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 3 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 39 from PMID 41688618: 'These preclinical results underline the potential benefit of radiolabeled 4AH29 over FAP-2286 due to its enhanced tumor retention and more pronounced anti-tumor effects warranting clinical investigation.'.